Loading...
19 fluvoxamine COVID-19 controlled studies, 9 RCTs
https://c19early.org/fmeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ STOP COVID Lenze (DB RCT) 93% 0.07 [0.01-0.52] 1,200mg progression 0/80 6/72 Improvement, RR [CI] Dose (4d) Treatment Control STOP COVID Lenze (DB RCT) 82% 0.18 [0.05-0.65] 1,200mg hosp. 1/80 5/72 Seftel (QR) 84% 0.16 [0.01-3.29] 500mg death/ICU 0/77 2/48 Seftel (QR) 94% 0.06 [0.01-0.37] 500mg hosp. 0/77 6/48 Seftel (QR) 99% 0.01 [0.00-0.21] 500mg no recov. 0/77 29/48 STOP COVID 2 Reiersen (DB RCT) -201% 3.01 [0.12-73.6] 800mg oxygen 1/272 0/275 STOP COVID 2 Reiersen (DB RCT) 33% 0.67 [0.24-1.87] 800mg oxygen 6/272 9/275 STOP COVID 2 Reiersen (DB RCT) 38% 0.62 [0.16-2.46] 800mg oxygen 3/164 6/205 STOP COVID 2 Reiersen (DB RCT) 9% 0.91 [0.38-2.20] 800mg hosp. 9/272 10/275 STOP COVID 2 Reiersen (DB RCT) 12% 0.88 [0.42-1.81] 800mg progression 13/272 15/275 Seo (SB RCT) 0% 1.00 [0.15-6.57] 800mg progression 2/26 2/26 Seo (SB RCT) 34% 0.66 [0.06-6.73] 800mg progression 1/19 2/25 Seo (SB RCT) 13% 0.87 [0.71-1.06] 800mg progression 26 (n) 26 (n) COVID-OUT Bramante (DB RCT) -11% 1.11 [0.33-3.61] 400mg death/hosp. 6/329 5/324 OT1 COVID-OUT Bramante (DB RCT) -16% 1.16 [0.58-2.25] 400mg progression 18/329 15/324 OT1 COVID-OUT Bramante (DB RCT) 2% 0.98 [0.29-3.37] 400mg hosp. 5/329 5/324 OT1 COVID-OUT Bramante (DB RCT) 2% 0.98 [0.29-3.37] 400mg hosp. 5/329 5/324 OT1 COVID-OUT Bramante (DB RCT) 5% 0.95 [0.72-1.25] 400mg progression 79/329 80/321 OT1 Pineda 94% 0.06 [0.01-0.52] 800mg death 1/594 4/63 Pineda 73% 0.27 [0.14-0.54] 800mg oxygen 15/594 13/63 Pineda 51% 0.49 [0.26-0.95] 800mg hosp. 23/594 11/63 Pineda -71% 1.71 [0.94-3.14] 800mg hosp. time 23 (n) 11 (n) Farahani (DB RCT) 51% 0.49 [0.24-1.02] 400mg PASC 42 (n) 43 (n) LONG COVID Farahani (DB RCT) 44% 0.56 [0.23-1.37] 400mg PASC 6/42 11/43 LONG COVID Farahani (DB RCT) 62% 0.38 [0.11-1.35] 400mg PASC 3/42 8/43 LONG COVID Farahani (DB RCT) 52% 0.48 [0.25-0.95] 400mg PASC 9/42 19/43 LONG COVID Farahani (DB RCT) 49% 0.51 [0.14-1.91] 400mg PASC 3/42 6/43 LONG COVID Farahani (DB RCT) 59% 0.41 [0.08-2.00] 400mg PASC 2/42 5/43 LONG COVID Farahani (DB RCT) -17% 1.17 [0.47-2.94] 400mg PASC 8/42 7/43 LONG COVID Farahani (DB RCT) 8% 0.92 [0.42-2.04] 400mg PASC 9/42 10/43 LONG COVID Farahani (DB RCT) 74% 0.26 [0.03-2.20] 400mg PASC 1/42 4/43 LONG COVID Farahani (DB RCT) 85% 0.15 [0.02-1.14] 400mg PASC 1/42 7/43 LONG COVID Farahani (DB RCT) 37% 0.63 [0.29-1.36] 400mg PASC 8/42 13/43 LONG COVID Farahani (DB RCT) 27% 0.73 [0.25-2.12] 400mg PASC 5/42 7/43 LONG COVID Farahani (DB RCT) 6% 0.94 [0.75-1.17] 400mg PASC 32/42 35/43 LONG COVID TOGETHER Reis (DB RCT) -200% 3.00 [0.12-73.5] 800mg death 1/738 0/738 CT2 TOGETHER Reis (DB RCT) 12% 0.88 [0.32-2.40] 800mg hosp. 7/738 8/738 CT2 TOGETHER Reis (DB RCT) 50% 0.50 [0.25-0.92] 800mg progression 13/738 27/738 CT2 EFFaCo Siripongbo.. (RCT) -2% 1.02 [0.26-4.00] 400mg oxygen 4/162 4/165 EFFaCo Siripongbo.. (RCT) -22% 1.22 [0.38-3.93] 400mg hosp. 6/162 5/165 Tsiakalos 67% 0.33 [0.01-7.84] 800mg ICU 0/53 1/50 Tsiakalos 84% 0.16 [0.02-1.26] 800mg hosp. 1/53 6/50 Tsiakalos 86% 0.14 [0.02-0.74] 800mg progression 2/53 8/50 TOGETHER Reis (DB RCT) 30% 0.70 [0.37-1.26] 800mg death 17/741 25/756 TOGETHER Reis (DB RCT) 91% 0.09 [0.01-0.47] 800mg death 1/548 12/618 TOGETHER Reis (DB RCT) 22% 0.78 [0.46-1.28] 800mg ventilation 26/741 34/756 TOGETHER Reis (DB RCT) 22% 0.78 [0.61-1.03] 800mg hosp. 75/741 97/756 TOGETHER Reis (DB RCT) 32% 0.68 [0.52-0.88] 800mg hosp./ER 79/741 119/756 TOGETHER Reis (DB RCT) 31% 0.69 [0.53-0.90] 800mg hosp./ER 78/740 115/752 TOGETHER Reis (DB RCT) 66% 0.34 [0.21-0.54] 800mg hosp./ER 541 (n) 609 (n) TOGETHER Reis (DB RCT) -49% 1.49 [0.94-2.38] 800mg viral+ 167/207 163/221 Calusic (ICU) 42% 0.58 [0.36-0.94] 1,200mg death 30/51 39/51 ICU patients Kirenga 68% 0.32 [0.19-0.53] 800mg death 29/94 126/222 Kirenga 53% 0.47 [0.23-0.97] 800mg recovery 94 (n) 222 (n) ACTIV-6 Naggie (DB RCT) 31% 0.69 [0.27-1.21] 700mg progression 14/589 21/586 ACTIV-6 Naggie (DB RCT) 34% 0.66 [0.23-1.16] 700mg clin. ord. 589 (n) 586 (n) ACTIV-6 Naggie (DB RCT) -15% 1.15 [0.51-1.83] 700mg clin. ord. 589 (n) 586 (n) ACTIV-6 Naggie (DB RCT) 6% 0.94 [0.29-1.74] 700mg clin. ord. 589 (n) 586 (n) ACTIV-6 Naggie (DB RCT) -1% 1.01 [0.92-1.12] 700mg no recov. 589 (n) 586 (n) ACTIV-6 Naggie (DB RCT) 49% 0.51 [0.05-5.64] 700mg hosp. 1/589 2/586 Oskotsky (PSM) -58% 1.58 [0.42-5.93] n/a death 2/11 19/165 Oskotsky (PSM) 26% 0.74 [0.55-0.99] n/a death 48/481 956/7,215 Fritz 19% 0.81 [0.26-2.22] n/a hosp./ER 4/17 1,896/20,457 Fritz 12% 0.88 [0.79-0.99] n/a hosp./ER 707/3,414 1,896/20,457 Fritz 12% 0.88 [0.77-0.99] n/a hosp./ER 559/2,744 1,896/20,457 Fritz 10% 0.90 [0.81-0.99] n/a hosp./ER 971/4,577 1,896/20,457 Diaz (PSM) 28% 0.72 [0.63-0.81] n/a cases 4,558 (n) 4,558 (n) Trkulja (PSM) 27% 0.73 [0.35-1.55] n/a death Trkulja (PSM) -37% 1.37 [0.56-3.33] n/a hosp. Visos-Varela -103% 2.03 [0.24-17.4] n/a death case control Visos-Varela -395% 4.95 [0.34-71.4] n/a ICU case control Visos-Varela 40% 0.60 [0.19-1.92] n/a hosp. case control Visos-Varela 32% 0.68 [0.18-2.50] n/a progression case control Visos-Varela 12% 0.88 [0.54-1.43] n/a cases case control Fluvoxamine COVID-19 outcomes c19 earlyOctober 2023 1 OT: comparison with other treatment 2 CT: study uses combined treatment Favors fluvoxamine Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
